CANSF - Company Exploring CBG Production Signals New Era Of Commercial Success In Synthetic Biology | Benzinga
Biotech company Willow Biosciences Inc. (TSX:WLLW) (OTCQB:CANSF) generated nearly $1.3 million in revenues in 2023, increasing approximately 60% over the period.
Dr. Chris Savile, president and CEO of the company called 2023 a "transformative year for Willow," which relies on synthetic biology techniques to create compounds like cannabigerol typically extracted from cannabis.
Why?
In its Wednesday press release, the company said one of its top achievements over the past 12 months was the launch of BioOxi bio-oxidation platform technology.
The AI-driven selective hydroxylation platform has been proven to remove multiple chemical steps and significantly reduce the cost of manufacturing target molecules.
The new technology allowed Willow to accelerate its "path to nearer-term and potentially larger revenue opportunities while reducing operational expenses."
In 2023, the company also engaged in multiple partnerships with innovators, such as Kalsec, an undisclosed Nasdaq-listed biopharmaceutical company and generic pharmaceutical companies, such as Suanfarma. These ...